Patent 11771683 was granted and assigned to Actelion on October, 2023 by the United States Patent and Trademark Office.
The present invention relates to a dosing regimen for (R)-5-[3-chloro-4-(2,3-dihydroxy-propoxy)-benz[Z]ylidene]-2-([Z]-propylimino)-3-o-tolyl-thiazolidin-4-one.